Regeneron Pharmaceuticals, Inc. (REGN) NASDAQ
769.74
+20.4508(+2.73%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
769.74
+20.4508(+2.73%)
Currency In USD
| Previous Close | 749.29 |
| Open | 755.8 |
| Day High | 774.26 |
| Day Low | 755.8 |
| 52-Week High | 821.11 |
| 52-Week Low | 476.49 |
| Volume | 231,850.46 |
| Average Volume | 756,391 |
| Market Cap | 79.98B |
| PE | 18.57 |
| EPS | 41.46 |
| Moving Average 50 Days | 763.59 |
| Moving Average 200 Days | 659.03 |
| Change | 20.45 |
Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment
GlobeNewswire Inc.
Mar 11, 2026 1:29 AM GMT
$250,000 top award goes to Connor Hill in America’s longest running and most distinguished science and math competitionTARRYTOWN, N.Y. and WASHINGTON, March 10, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for
Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients
GlobeNewswire Inc.
Mar 09, 2026 11:00 AM GMT
Patients treated with olatorepatide achieved up to 19% body-weight loss at week 48 Regeneron’s global Phase 3 registrational program to be initiated later this year TARRYTOWN, N.Y., March 09, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc
Regeneron Announces Investor Conference Presentation
GlobeNewswire Inc.
Mar 05, 2026 9:05 PM GMT
TARRYTOWN, N.Y., March 05, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation at the Barclays 28th Annual Global Healthcare Conference at 9:00 a.m. ET on Tuesday, March 10, 2026. The sessio